Introduction Organoids are 3D, miniaturized organs that are generally grown from stem cells (pluripotent or adult) that self-organize in vitro
Regulatory Shifts and Validation: Key Insights from The World Congress on Alternatives and Animal Use in the Life Sciences Conference (WC13)
I, (Dr. Tomasz Kostrweski, CSO, CN Bio) recently had the pleasure of attending the 13th World Congress on Alternatives and Animal Use in the Life
Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies
Knowing a drug’s bioavailability during lead optimization is crucial as it directly influences dosing strategy, therapeutic efficacy, safety margins,
Microphysiological systems for mAbs development: how do they address animal limitations?
Welcome to part two of our blog series exploring the FDA’s announcement to phase out the animal testing requirement for monoclonal antibodies (mAbs),
Why the FDA animal testing phase-out for monoclonal antibodies?
In a groundbreaking press release on April 10th, 2025, the FDA announced its decision to phase out animal testing requirements for monoclonal
The Rise of Oligonucleotide Therapeutics: Overcoming ADMET Development Challenges with Human-Centric Approaches
New modality drugs, or advanced oligonucleotide therapeutics, refer to innovative approaches that go beyond traditional small molecule approaches to
Evaluating Caco-2 cell’s gold-standard status in absorption, permeability and bioavailability studies: Are their limitations justified?
In the realm of pharmaceutical research, Caco-2 cells have long been heralded as the gold standard for studying intestinal absorption and
CN Bio e-Symposium (User Group Meeting) 2024 – Recap
6 Challenges in ADME Drug Development
When developing drugs, we rely heavily on in vitro, in vivo animal and in silico models to predict how the human body will interact with drugs before